Alveolar soft part sarcoma in children and adolescents: A report from the soft-tissue sarcoma italian cooperative group

M. Casanova, A. Ferrari, G. Bisogno, G. Cecchetto, E. Basso, B. De Bernardi, P. Indolfi, F. Fossati Bellani, M. Carli

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Alveolar soft part sarcoma (ASPS) is a rare malignant tumor and little is known about its clinical features and management. We report on a series of 19 pediatric patients managed over 20 years. Patients and methods: Primary conservative surgery was performed in all patients and was radical in nine, non-radical in three; seven patients underwent biopsy alone (3 unresectable tumors, 4 metastatic disease). In two cases radical surgery was performed after primary chemotherapy. Radiotherapy was delivered to 8 patients, chemotherapy to 15. Results: After a median follow-up of 74 months, the five-year survival was 80% for the whole series, 91% for patients with localized disease, 100% for patients with tumor ≤ 5 cm, and 31% for those > 5 cm; 16 of 19 patients were alive (12 of 12 with grossly-resected tumor in first continuous remission). Chemotherapy achieved two partial remission among seven evaluable patients. Conclusions: Pediatric ASPS has a more favorable prognosis than its adult counterpart. In this series, tumor size correlates with metastatic disease at onset and is the major factor influencing survival. Surgery is the mainstay of therapy. The effectiveness of adjuvant therapy remains to be established, though radiotherapy may be advisable in cases of inadequate surgery.

Original languageEnglish
Pages (from-to)1445-1449
Number of pages5
JournalAnnals of Oncology
Volume11
Issue number11
Publication statusPublished - 2000

Keywords

  • Alveolar soft part sarcoma
  • Pediatric tumors
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Alveolar soft part sarcoma in children and adolescents: A report from the soft-tissue sarcoma italian cooperative group'. Together they form a unique fingerprint.

Cite this